Approximately 280 roles preserved as company intends to retain employees and expand the capability of the site over time.
Amgen To Purchase Pfizer’s Manufacturing Facility In Dun Laoghaire
Approximately 280 roles preserved as company intends to retain employees and expand the capability of the site over time
Dublin, Ireland (March 11, 2011) - Amgen Inc. and Pfizer Inc. today announced that they have signed an agreement for the sale of Pfizer’s manufacturing facility located at Dun Laoghaire, County Dublin to Amgen. The transaction is expected to close in the second quarter of this year.
The Pfizer facility is a 37,000 square-meter aseptic operations facility with freeze dry product and liquid vial filling operations. The transaction anticipates that the majority of the employees at the site (approximately 240) will transfer their employment to Amgen and Pfizer will consult with transferring colleagues in relation to the implications of the transfer for them. A smaller group (about 40) will remain employed by Pfizer as part of the terms of the agreement.
“As we expand internationally, the Dublin site will help us deliver a growing supply of Amgen medicines for patients worldwide,” said Madhu Balachandran, senior vice president, Amgen Manufacturing. “We are impressed with the technical expertise and commitment to excellence demonstrated by the employees who work at the Dun Laoghaire site and look forward to welcoming them to Amgen’s global manufacturing team.”
Balachandran continued, “We are grateful to the Irish government and IDA Ireland for their support in helping us secure this world-class facility and look forward to a strong, productive relationship in the years ahead.”
Welcoming the announcement, Dr Paul Duffy, Vice President Primary Care, Pfizer Global Supply said, “This is a good day for colleagues and for Ireland Inc. as it proves we remain an attractive location for high calibre investment. We worked determinedly to sell the Dublin facility in order that employment could be retained and I wish to thank colleagues for their continued commitment throughout the process. We continue to actively engage in exploring opportunities to divest our Loughbeg and Shanbally plants in Cork and remain focused on delivering successful outcomes.”
Under terms of the agreement, Amgen will manufacture Pfizer’s products at the facility for an interim period and Pfizer will lease a portion of the facility from Amgen for an interim period. Amgen intends to develop the capability to formulate and fill its biological products at the site and expand the manufacturing capabilities there over time.
Commenting on the announcement by Amgen to take over the Pfizer facility in Dun Laoghaire, Barry O’Leary, CEO of IDA Ireland said, “This investment by Amgen, the largest biotechnology company in the world, gives a substantial boost to Ireland’s Life Sciences sector. Today’s announcement represents a significant win for Ireland due to Amgen’s leading position in the industry and the strategic nature of the proposed development for the company.”
“The retention of the 240 jobs by Amgen and the 40 staff who will remain employed by Pfizer, in Dun Laoghaire, is also very welcome news for staff and management here and is testament to the hard work and dedication with which they continued to operate this facility during a difficult and uncertain period. I wish all parties involved every success with this acquisition and to offer the full support of IDA Ireland to Amgen as it develops its operations here in Ireland.”
Amgen has conducted commercial operations in Ireland since 2000 and employs about 25 staff members at its offices in North County Dublin.
Published: 11th March 2011.